Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ...
Profound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease
TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...
Zacks Investment Research on MSN
Profound Medical (PROF) surges 13.0%: Is this an indication of further gains?
Profound Medical (PROF) shares rallied 13% in the last trading session to close at $5.82. This move can be attributable to notable volume with a higher number of shares being traded than in a typical ...
– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA ...
TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...
TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results